Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 2Phase NA 1Phase 4 1Phase 3 1Phase 2/3 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 108Gastrointestinal 108CNS 8Gynecologic 6Endocrine 5Head & Neck 3Genitourinary 3Other hematologic neoplasm 2Dermatologic 2Thoracic 1Plasma cell 1Other 1NET 1Classical hematology 1Breast 1

Conditions

Leukemia, Myeloid, Acute 985Leukemia 733Leukemia, Lymphocytic, Chronic, B-Cell 665Precursor Cell Lymphoblastic Leukemia-Lymphoma 605Myelodysplastic Syndromes 502Lymphoma 340Leukemia, Myelogenous, Chronic, BCR-ABL Positive 308Lymphoma, Non-Hodgkin 294Hematologic Neoplasms 257Lymphoma, Follicular 223Multiple Myeloma 213Burkitt Lymphoma 209Hodgkin Disease 198Lymphoma, Large B-Cell, Diffuse 194Lymphoma, Mantle-Cell 193Lymphoma, B-Cell, Marginal Zone 189Leukemia, Myelomonocytic, Chronic 181Leukemia, Myeloid, Chronic-Phase 171Recurrence 167Myeloproliferative Disorders 165Congenital Abnormalities 140Lymphoma, Large-Cell, Immunoblastic 132Leukemia, Myeloid, Accelerated Phase 118Blast Crisis 115Anemia, Refractory, with Excess of Blasts 114Waldenstrom Macroglobulinemia 103Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 102Primary Myelofibrosis 94Graft vs Host Disease 88Neoplasms, Plasma Cell 84

Interventions

trametinib 1dabrafenib 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Gastrointestinal Stromal Tumors × Other hematologic neoplasm × Clear all
NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

NCT01831726 2017-03-20

SIGNATURE

Novartis

Phase 2 Completed
80 enrolled 9 charts
DermatologicGastrointestinalGynecologicHead & NeckOther hematologic neoplasmSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Thyroid Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡